Your browser doesn't support javascript.
loading
The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018-2019).
Bonanni, Paolo; Faivre, Pascaline; Lopalco, Pier Luigi; Joura, Elmar A; Bergroth, Tobias; Varga, Stefan; Gemayel, Nathalie; Drury, Rosybel.
Afiliación
  • Bonanni P; Department of Health Sciences, University of Florence , Florence, Italy.
  • Faivre P; Market Access Vaccines, MSD , Lyon, France.
  • Lopalco PL; Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa , Pisa, Italy.
  • Joura EA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center, Medical University of Vienna , Vienna, Austria.
  • Bergroth T; Center for Observational and Real-world Evidence, MSD , Stockholm, Sweden.
  • Varga S; Center for Observational and Real-world Evidence, Merck & Co, Inc , Kenilworth, NJ, USA.
  • Gemayel N; Health Economics & Market Access, Amaris Consulting , Barcelona, Spain.
  • Drury R; Global Vaccines Medical & Scientific Affairs, MSD , Lyon, France.
Expert Rev Vaccines ; 19(11): 1073-1083, 2020 11.
Article en En | MEDLINE | ID: mdl-33267673
ABSTRACT

Background:

There is a need to better understand HPV vaccination (HPVv) implementation in WHO Europe Region (WHO/ER), including recommendations, funding, and vaccination coverage rates (VCR).

Methods:

A targeted literature review (up to 31 January 2020) was conducted using national health ministry websites, WHO database, and published studies from WHO/ER countries (n = 53). HPVv recommendations and funding data (target age, gender, schedule, setting, target and monitored VCR) for primary and catch-up cohorts were collected.

Results:

National recommendations for HPVv exist in 46/53 (87%) countries, of which 38 (83%), 2 (4%), and 6 (13%) countries provided full, partial, or no funding, respectively, for the primary cohort. Fully or partially funded HPVv was provided for girls only in 25/53 (47%) countries and for both boys and girls in 15/53 (28%) countries. HPVv catch-up was fully or partially funded in 14/53 (26%) countries. Among 40 countries with a national immunization program (NIP), monitored VCRs ranged from 4.3% to 99% (n = 30). Of the 10 countries reporting VCR targets, only Portugal exceeded its target.

Conclusion:

Of the 53 WHO/ER countries, 40 have funded HPVv NIPs, among which 30 report VCRs. Additional efforts are required to ensure HPVv NIPs are fully funded and high VCRs maintained.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 10_ODS3_salud_sexual_reprodutiva / 11_ODS3_cobertura_universal / 1_ASSA2030 / 2_ODS3 Problema de salud: 10_sexually_transmitted_infections / 11_financial_arrangements / 1_doencas_transmissiveis / 2_cobertura_universal / 2_enfermedades_transmissibles Asunto principal: Vacunación / Infecciones por Papillomavirus / Vacunas contra Papillomavirus Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Expert Rev Vaccines Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 10_ODS3_salud_sexual_reprodutiva / 11_ODS3_cobertura_universal / 1_ASSA2030 / 2_ODS3 Problema de salud: 10_sexually_transmitted_infections / 11_financial_arrangements / 1_doencas_transmissiveis / 2_cobertura_universal / 2_enfermedades_transmissibles Asunto principal: Vacunación / Infecciones por Papillomavirus / Vacunas contra Papillomavirus Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Expert Rev Vaccines Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Italia
...